Latest Stories
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may have investors wondering how to approach the situation.
2 Reasons to Like CACI (and 1 Not So Much)
Since March 2021, the S&P 500 has delivered a total return of 72.6%. But one standout stock has more than doubled the market - over the past five years, CACI has surged 180% to $630.12 per share. Its momentum hasn’t stopped as it’s also gained 29.6% in the last six months thanks to its solid quarterly results, beating the S&P by 26.5%.
3 Reasons to Sell DOLE and 1 Stock to Buy Instead
Over the past six months, Dole has been a great trade, beating the S&P 500 by 11%. Its stock price has climbed to $15.35, representing a healthy 14% increase. This performance may have investors wondering how to approach the situation.
3 Reasons to Avoid GLDD and 1 Stock to Buy Instead
What a fantastic six months it’s been for Great Lakes Dredge & Dock. Shares of the company have skyrocketed 41.2%, hitting $16.92. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
3 Reasons AD is Risky and 1 Stock to Buy Instead
Array currently trades at $49.06 per share and has shown little upside over the past six months, posting a small loss of 3.8%. The stock also fell short of the S&P 500’s 3.1% gain during that period.
3 Reasons to Sell PB and 1 Stock to Buy Instead
Since September 2025, Prosperity Bancshares has been in a holding pattern, floating around $67.60.
IBM (IBM): Buy, Sell, or Hold Post Q4 Earnings?
IBM has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $252.87.
3 Reasons to Sell CSCO and 1 Stock to Buy Instead
Cisco’s 11.6% return over the past six months has outpaced the S&P 500 by 8.5%, and its stock price has climbed to $76.02 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Advertising Software Stocks Q4 Results: Benchmarking LiveRamp (NYSE:RAMP)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the advertising software industry, including LiveRamp (NYSE:RAMP) and its peers.
Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - specialty stocks fared in Q4, starting with Enovis (NYSE:ENOV).